Introduction {#Sec1}
============

Bladder Cancer is a common name for urothelial cell carcinoma (the lining of the urinary tract from the pelvis to the urethra), and it is the most common malignancies of the urinary tract \[[@CR1], [@CR2]\]. In 2015, the prevalence of this cancer in the United States was reported to be 74,000, of which approximately 16,000 were fatal \[[@CR3]\]. According to epidemiological studies, more than 90% of bladder cancer cases diagnosed in North America and Europe are categorized as urothelial carcinoma. Bladder cancer is mainly classified into non-muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC) \[[@CR4]\]. NMIBC, as a highly prevalent bladder cancer with a 50--70% recurrence rate, accounts for 75% of all bladder cancer cases. The remaining cases diagnosed with MIBC have a higher rate of mortality \[[@CR5]\]. According to the grading system of the bladder cancer, 70% of bladder cancer cases are diagnosed as low-grade, non-invasive with superficial papillary growing. High-grade bladder cancer is characterized by the progression of invasive tumors and diagnosed in 30% of patients with bladder cancer \[[@CR6]\].

Oxidative stress, defined as a disturbance in the balance between reactive oxygen species (ROS) production and antioxidant agents, can alter the redox homeostasis into the cells and leads to oxidative damage to the DNA and may contribute to the tumor progression and development \[[@CR7], [@CR8]\]. Mitochondria, as the powerhouse of the cells, is considered the major source of ROS production in various cells \[[@CR9]\].

One of the most significant proteins involved in the production and regulation of Reactive Oxygen Species (ROS) is *ROS Modulator 1 (ROMO1)*. *ROMO1* is a mitochondrial protein that was first identified in cancerous tissues in 2006, as a group of researchers found that some cancerous tissues develop drug resistance during chemotherapy \[[@CR10]--[@CR12]\]. It was reported that ROMO1 was localized in the mitochondria and play a pivotal role in maintaining the redox signaling in normal and cancer cells \[[@CR13]\]. *ROMO1*, a ROS modulator protein, was characterized in various cancer cells, and also implicated in the invasion and development of cancer cells \[[@CR10], [@CR14]\]. ROS can lead to proliferation and metastasis through different pathways, including *NF-κB, ERK, MAPK, p53*, and *PI3-K* in various types of cancer \[[@CR10], [@CR15], [@CR16]\]. Also, in-vitro studies performed on ROMO1 demonstrated the carcinogenicity of this protein in a few cases \[[@CR10], [@CR14]\]. In previous studies conducted on hepatic carcinoma, it has been suggested that increased gene expression of ROMO1 in cancerous tissues may be responsible for invasion and growth of tumor cells, which could be considered a useful biomarker for the diagnosis and treatment of different neoplasms \[[@CR10], [@CR14]\]. Increased *ROMO1* gene expression in tumor cells cause excessive ROS production and followed damage to mitochondrial DNA and nucleus \[[@CR14]\]. Besides, it has been reported that *ROMO1*-induced ROS overproduction is associated with the recurrence of various cancer types \[[@CR14], [@CR17]\]. However, it is worth noting that *ROMO1*-induced ROS production is also essential for normal cells \[[@CR18]\]. Not only is *ROMO*-1 requisite for physiological functions of mitochondria to generate ROS, but it also plays a critical role in the maintenance of the morphology of mitochondria and the integrity of their inner membrane structures \[[@CR14], [@CR19]\]. In addition to the effect of *ROMO1* on free radical production, *ROMO1* can also affect the cell cycle process, as decreased expression of this protein causes cell cycle arrest at the *G2/M* stage \[[@CR19]\]. Aberrant *ROMO1* expression can enhance the generation ROS in normal cells which can transform these cells into cancer cells \[[@CR20]\]. However, *ROMO1* expression and then induced oxidative stress have not been studied in bladder cancer. In the present study, we demonstrated that the *ROMO1* gene expression and its serum level, as well as induced oxidative stress, are critical for bladder cancer progression and positively correlated with bladder cancer higher grade.

Materials and methods {#Sec2}
=====================

Patients and study design {#Sec3}
-------------------------

The study protocol was reviewed and approved by the Ethics Committee of Hamadan University of Medical Sciences. A total of 35 bladder cancer patients and 35 healthy controls were consecutively recruited between April 2019 and January 2020 from Shahid Beheshti Hospital of Hamadan, Iran. Written informed consent was obtained from all patients and control participants. Bladder cancer tissue specimens were obtained from patients who underwent transurethral resection of bladder cancer. The diagnosis of cancerous tissues and their grading system was performed by a trained pathologist based on standard protocols. Bladder cancerous and healthy adjacent tissues were surgically obtained from 35 patients and divided into two parts; one part was frozen in liquid nitrogen and specified for RNA extraction, cDNA synthesis, and gene expression analysis, while the other part was fixed in 10% formalin for pathological examinations. Blood samples were also collected from patients with bladder cancer, as well as age and sex-matched healthy individuals. Sera were isolated from the whole blood specimens and stored at − 70 °C for the biochemical assay. Demographic characteristics, such as age, sex, site of primary neoplasm, date of diagnosis, family history of cancer, and history of the other diseases were recorded. Subjects with acute or chronic disorders, other malignancies, and a history of chemotherapy and radiotherapy were excluded from the study.

Transurethral resection (TUR) of bladder tumor {#Sec4}
----------------------------------------------

Following the cystoscopy procedure, patients with cell abnormalities were selected to undergo Transurethral resection (TUR) of bladder tumors. In this procedure, cancerous tissues are removed and histopathologically graded by a trained pathologist.

Pathological examination {#Sec5}
------------------------

Bladder cancer and normal-appearing adjacent tissue samples were immediately fixed using formalin 10% and then embedded in paraffin. The prepared sections were examined with hematoxylin and eosin staining and reviewed by a pathologist. For this propose, tissue sections at a thickness of 5 µm were first stained using with Harris' hematoxylin solution for 10 min. Samples were washed in tap water until the water was colorless, then tissue specimens were differentiated using acid ethanol (1 ml concentrated HCl + 400 ml 70% ethanol in water). Next, after rinsing in tap water for 2 min, samples were stained with the eosin Y ethanol solution. Finally, the stained sections were cleared using xylene and then mounted on slides and coverslipped. H&E stained tissue sections were examined under light microscopy, and appropriate samples were selected for the analysis. Samples stained with H&E are shown in Fig. [1](#Fig1){ref-type="fig"}.Fig. 1Hematoxylin and eosin staining of bladder carcinoma. **a** normal appearing bladder adjacent tissue (H&E staining; Bar = 100 μm); **b** fibrovascular core in the center of projection (star) (H&E staining; Bar = 60 μm); **c** tumor cells with slight size variation, mild loss of cellular polarity and mildly abnormal chromatin (H&E staining; Bar = 25 μm); **d** A few mitosis near to the basal lamina (arrows) (H&E staining; Bar = 25 μm)

RNA extraction and real-time PCR {#Sec6}
--------------------------------

Total RNA was extracted using the RNX-Plus solution (Cinnagen, Tehran, Iran) according to the manufacturer's protocols. The extracted RNA was quantitatively and qualitatively evaluated by nanodrop (Thermo Fisher Scientific Inc., USA) and 1% agarose gel, respectively. Complementary DNA (cDNA) was then synthesized with Revert Aid TM First Strand cDNA Synthesis Kit (Fermentas). Real-time PCR was performed by SYBR Green master mix (Amplicon, Denmark) in the Light Cycler 96 instruments (Roche Life Science Deutschland GmbH, Sandhofer, Germany). Specific Primer sets were designed in accordance with the GenBank database (<https://www.ncbi.nlm.nih.gov>) and synthesized by Takapou Zist Company. The primer sequences were as follows: *ROMO1* (Forward: 5ʹ-CTGTCTCAGGATCGGAATGCG-3ʹ; Reverse: 5ʹ- CATCGGATGCCCATCCCAATG-3ʹ) and *beta-actin* (Forward: 5ʹ-ACAGAGCCTCGCCTTTGC − 3ʹ; Reverse: 5ʹ-ATCACGCCCTGGTGCCT − 3ʹ). The difference in the relative gene expression in comparison with the reference gene was estimated using the 2\^-ΔΔCT formula \[[@CR21]\].

Measurement of serum total antioxidant capacity (TAC) {#Sec7}
-----------------------------------------------------

For the determination of Total Antioxidant Capacity (TAC), ferric reducing antioxidant power (FRAP) was measured. In this method, the reduction of the ferric (Fe III) tripyridyltriazine (TPTZ) complex to Fe II can be determined at low pH by measuring the optical absorption at a wavelength of 593 nm \[[@CR22]\].

Measurement of serum total oxidant status (TOS) {#Sec8}
-----------------------------------------------

Total Oxidant Status (TOS) of the serum samples was assessed by oxidation of ferrous iron to ferric ion in moderate acidic pH values in samples utilizing xylenol orange. The optical intensity of specimens was measured at a wavelength of 560 nm \[[@CR23]\].

Measurement of ROMO-1 contents in the serum of patients and healthy subjects {#Sec9}
----------------------------------------------------------------------------

The serum levels of ROMO1 was analyzed by the commercially available ELISA kit (Bioassay Technology Laboratory, E2143Hu) in sera of patients and healthy individuals according to the manufacturer's recommendations. All serum specimens were tested blinded.

Data analysis {#Sec10}
-------------

The statistical analysis was performed by SPSS software version 16 (SPSS Inc., Chicago, IL). To compare the relative expression ratios of this gene between the two study groups, the normal distribution of data was evaluated by the Kolmogorov-Smirnov test, and the proportions of the results of parametric and non-parametric variables were assessed using Mann-Whitney and Student T-tests. In this study, the p-value of less than 0.05 was statistically considered significant. The Spearman and Pearson correlation coefficients were used to analysis of the relationship between variables in terms of parametric and non-parametric proportions.

Results {#Sec11}
=======

Demographic characteristics of participants {#Sec12}
-------------------------------------------

A total of 35 cancerous, along with 35 adjacent healthy tissues, were taken from patients diagnosed with bladder cancer (Table [1](#Tab1){ref-type="table"}). Fifteen patients (42.85%) were under 67 years old, while the rest (57.14%) were over 67 years old. Notably, histopathological analyses of the obtained samples were carried out according to the WHO urothelial bladder carcinoma grading system \[[@CR24]\]. Specimens were graded as Grade I (13/35), Grade II (11/35), and Grade III (6/35). Seven patients (20%) were diagnosed with multifocal bladder cancer, while 28 patients (80%) had no signs of multifocal bladder cancer.

Table 1Clinicopathological parameters of bladder cancer patients (n = 35)CharacteristicCategorizationN (%)F.C. of ROMO1\
Mean ± SDP valueSerum ROMO1 Mean ± SDP valueAge, years≦ 6715 (42.85)7.13 ± 2.490.4122.57 ± 0.760.544\> 6720 (57.14)7.77 ± 2.042.39 ± 0.91SmokingYes24 (68.58)7.87 ± 2.040.1392.56 ± 0.930.363No11 (31.42)6.66 ± 2.502.27 ± 0.60GradeGrade I13 (37.14)5.17 ± 1.99\< 0.0012.02 ± 0.70\< 0.001Grade II16(45.71)8.33 ± 0.662.42 ± 0.74Grade III6 (17.14)9.77 ± 1.513.50 ± 0.49Tumor size, cm≦ 2.021 (60.0)6.88 ± 2.240.0462.34 ± 0.730.273\> 2.014 (40.0)8.41 ± 1.952.66 ± 0.98MultifocalityMultifocality7 (20.0)9.26 ± 1.730.0382.69 ± 0.920.193No multifocality28 (80.0)6.03 ± 1.942.24 ± 0.83

ROMO1 gene expression in cancerous and adjacent healthy tissues {#Sec13}
---------------------------------------------------------------

In this study, our findings demonstrated that the expression of ROMO1 was significantly correlated with tumor size (r = − 0.339, p = 0.046) and histopathological grading (r = 0.772, p \< 0.001) in bladder cancer patients (Fig. [2](#Fig2){ref-type="fig"}b). The expression level of the ROMO1 gene was evaluated in cancerous and healthy adjacent tissues and found that its expression was markedly higher in bladder cancerous tissues compared with adjacent healthy tissues (P \< 0.05, Fig. [2](#Fig2){ref-type="fig"}a). Also, we observed that the expression level of the ROMO1 gene was positively associated with its serum concentrations (p \< 0.001, r = 0.5816) (Fig. [3](#Fig3){ref-type="fig"}b).Fig. 2Serum levels of ROMO1 were significantly associated with ROMO1 gene expression. **a** Serum levels of ROMO1 were higher in bladder cancer when compared to control group. **b** there was a positive correlation between Serum levels of ROMO1 and its gene expression. **c** The ROC curve analysis for ROMO1 serum levels in patients with bladder cancer and control subjects. \*p \< 0.05 in all comparisonsFig. 3**a** Serum Level of TAC and TOS and OSI ratio bladder cancer patients and control group. **a** Serum Level of TAC was lower in bladder cancer patients. **b** Serum Level of TOS was higher in bladder cancer patients. **c** The OSI ratio was higher in bladder cancer as compared to control group. \*P\<0.05 is considered significant for all comparisons

Serum levels of ROMO1 were positively correlated with ROMO1 expression {#Sec14}
----------------------------------------------------------------------

The serum levels of ROMO1 was increased significantly in patients with bladder cancer in comparison with healthy individuals (P \< 0.05, Fig. [3](#Fig3){ref-type="fig"}a). A positive correlation was also detected between the serum level of ROMO1 and histopathological grading in patients with bladder cancer (r = 0.567, p \> 0.001) (Fig. [2](#Fig2){ref-type="fig"}c). Moreover, the Receiver Operating Characteristic (ROC) curve analysis was carried out to explore whether serum level of ROMO1 could be used as a potential marker for bladder tumors in 70 sample sets. The ROC curve analysis showed that an area under the curve (AUC) \[0.650 (95% CI 0.513--0.788)\] suggests that ROMO1 is capable of being applied as a tumor marker for bladder cancer (Fig. [3](#Fig3){ref-type="fig"}c).

Measurement of oxidative stress parameters {#Sec15}
------------------------------------------

### Level of TAC in serum patients and healthy individuals {#Sec142}

Total Antioxidant Capacity in serum specimens of patients with bladder cancer (n = 35) and healthy individuals (n = 35) was analyzed, and it was found that the parameter was markedly lower in serum samples of patients with bladder cancer in comparison with healthy subjects (P \< 0.05 Fig. [4](#Fig4){ref-type="fig"}).Fig. 4ROMO1 gene expression and serum protein level were positively associated with histopathological grading in bladder cancer. **a** ROMO1 gene expression was higher in bladder cancer. **b** ROMO1 gene expression was positively associated with histopathological grading in bladder cancer. **c** Serum level of ROMO1 was positively associated with histopathological grading in bladder cancer. \*p \< 0.05 in all comparisons

### Level of TOS in serum patients and healthy subjects {#Sec143}

The results indicated that the level of TOS in patients with bladder cancer was significantly higher when compared with healthy subjects (P \< 0.05, Fig. [4](#Fig4){ref-type="fig"}).

### OSI parameter {#Sec144}

Oxidative Stress Index (OSI) is defined by the ratio of TOS to TAC (Fig. [4](#Fig4){ref-type="fig"}). This index was significantly higher in \[patients with bladder cancer than that of healthy individuals (P \< 0.05).

Discussion {#Sec19}
==========

Oxidative stress can cause tumor growth, cell invasion, metastasis, and angiogenesis in cancer cells \[[@CR18], [@CR25]\]. Generally, increased levels of ROS can lead to cellular damage, inflammation, and DNA mutation, which may eventually result in the development of cancer \[[@CR18], [@CR25]\].

*ROMO1* is one of the most critical mitochondrial membrane proteins that can contribute to the regulation and production of ROS, as well as the protection of the mitochondrial membrane and its structure \[[@CR26]\]. The overexpression of *ROMO1* has been shown in different disorders, especially cancer. The excess levels of *ROMO1* can leads to an injury to the mitochondria structure and promotes oxidative stress in cells. However, *ROMO1* expression and possibly induced oxidative stress as well as its relationship with bladder cancer awaits investigation to clarify.

According to our findings, significant overexpression of the *ROMO1* gene was observed in bladder cancer tissues as compared with adjacent healthy tissues. Besides, in parallel with the increase in the expression of this gene, the serum levels of *ROMO1* were significantly elevated in patients with bladder cancer compared with healthy subjects. We also found a positive correlation between *ROMO1* expression and its serum concentrations.

Recently, Amini and colleagues have found that increased expression of *ROMO1* plays an essential role in the growth and development of gastric cancer \[[@CR27]\]. Several lines of evidence demonstrated that increased expression of *ROMO1* and oxidative stress are positively correlated to different pathologic conditions. For instance, Kim et al. have reported the overexpression of ROMO1 in colorectal cancer tissues. They also suggested that this protein might be considered a good candidate as a diagnostic biomarker \[[@CR28]\]. The study on *ROMO1* gene polymorphism showed that single nucleotide polymorphisms within the *ROMO1* gene along with other factors, such as H. Pylori infection and smoking, could be considered as risk factors for the development of gastric cancer \[[@CR29]\]. This study highlights the positive correlation between ROMO1 gene and protein expression and bladder cancer histological grading, which was in accordance with previously reported data that *ROMO1* was associated with higher grade and poor prognosis in other cancer types \[[@CR30]\].

Accordingly, we hypothesized that *ROMO1* overexpression facilitates ROS production and induces oxidative stress. To test this hypothesis, we have investigated the oxidative stress markers in the serum. Increased oxidative stress indices (TOS and OSI), along with decreased oxidative stress index (TAC), were observed in serum samples of patients with bladder cancer. ROS are involved in various physiological processes in normal cells; however, a certain level of ROS is required for the function of normal cells \[[@CR18]\]. Accumulation of ROS can affect cellular physiology, such as the aberrant activation of different metabolic pathways. It has been reported that induced oxidative stress can make cause detrimental effects on normal cell function and drive these cells to differentiate into cancer cells \[[@CR18]\]. As recently observed, free radical agents are increased parallel with the overexpression of *ROMO1*, which can impair the mitochondrial function. Therefore, in this research, we showed that parallel with an increase in the expression of *ROMO1*, the concentration of free radicals was elevated and led to the development of cancer. In line with present study results, a study performed on patients with esophageal cancer showed an increased level of TOS and OSI, as well as the decreased levels of TAC in patients \[[@CR31], [@CR32]\]. The research suggested that TOS and OSI can be used as biochemical indices for the diagnosis of esophageal cancer. As mentioned earlier, *ROMO1*, as a ROS modulator and regulator of the mitochondria function, has been detected in different types of cancers, and contribute to the progression and invasion of cancer cells, thereby various signaling and metabolic pathways. For example, ROS can activate both extracellular signal-regulated kinases (*ERK*) and *NF-kB* pathways \[[@CR15], [@CR33], [@CR34]\]. It has also been reported that oxidative stress strongly reduces the response of bladder cancer cells to Bacillus Calmette--Guérin (BCG) immunotherapy \[[@CR35]\]. BCG administration is the most functional intravesical treatment used for the treatment of bladder cancer. Most importantly, BCG immunotherapy may provide prophylaxis against COVID-19 in bladder cancer patients \[[@CR36]\]. On the other hand, it has been reported that the overexpression of ROMO1 can cause damages to the mitochondrial structure and an increment in oxidative stress \[[@CR18], [@CR37], [@CR38]\]; Accordingly, in patients with bladder cancer, ROMO1 overexpression may interfere with the prophylactic role of BCG immunotherapy against COVID-19. Additionally, it has been suggested that *ROMO1* could also influence the cell cycle at the *G2/M* stage; therefore, a decrease in the expression of *ROMO1* results in cell cycle arrest at the *G2/M* phase \[[@CR39]\]. As expected, our findings demonstrated that the expression of *ROMO1* was higher in comparison with healthy subjects that could stem from an oxidative stress condition, as the overexpression of *ROMO1* consequently leads to the disruption of mitochondrial membrane and its structure \[[@CR37]\], as well as Our findings indicated higher oxidative stress parameters in patients with bladder cancer. Collectively, it can be suggested that the overexpression of the *ROMO1* gene is linked with the development of bladder cancer.

In the present study, we also found that the overexpression of the *ROMO1* gene and protein expression had a significant correlation with the advanced grades of bladder cancer, and increased expression of this gene may promote cancer cell invasion, growth, and tumor tissue proliferation. It can be concluded that *ROMO1* plays a vital role in the development of bladder cancer, especially in advanced grades, and overexpression of this gene can be considered a prognostic marker for the screen of patients with bladder cancer. For this purpose, we have investigated the ROC curve analysis of serum *ROMO1* level. Interestingly, ROC curve analysis suggested that *ROMO1* could be considered as a potential tumor marker for bladder cancer. *ROMO1* has shown to be a potential biomarker in cancer and anticipate unfavorable prognosis in cancer \[[@CR27]\]. Finally, it can be concluded that this important mitochondrial protein can predispose individuals to develop bladder cancer, thereby increasing the level of free radical agents. Thus, the analysis of this gene/protein could be a useful biomarker for screening patients with bladder cancer.

Conclusions {#Sec20}
===========

We demonstrated that the overexpression of the *ROMO1* gene is associated with advanced grades of bladder cancer as well as an increase in oxidative stress conditions. These phenomena could be mediated via different signaling pathways, and finally led to cancer cell proliferation. It seems that the analysis of *ROMO1* is to be a useful prognostic marker to predict the survival of patients with bladder cancer, along with their response to different therapeutic agents. Further research is warranted to unravel the precise role of this mitochondrial protein in the development of bladder cancer.
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